Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3–9-month intervals following two-dose inactivated vaccine (CoronaVac)

Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3–9-month intervals following two-dose inactivated vaccine (CoronaVac)

BackgroundIn response to SARS-CoV-2 mutations and waning antibody levels after two-dose inactivated vaccines, we assessed whether a third dose of recombinant protein subunit vaccine (ZF2001) boosts immune responses.MethodsAn open-label single-center non-random trial was conducted on people aged 18 y...

Full description

Bibliographic Details
Main Authors: Yuting Liao, Yingping Chen, Bo Chen, Zhenzhen Liang, Xiaosong Hu, Bo Xing, Juan Yang, Qianhui Zheng, Qianhui Hua, Chuanfu Yan, Huakun Lv
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Immunology
Subjects:
COVID-19
heterologous booster
recombinant protein subunit vaccine
inactivated vaccine
immunogenicity
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1017590/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1017590/full

Similar Items